Key takeaways:
- Sanofi has announced a 78% reduction in the list price of its most widely prescribed insulin, Lantus, and a $35 monthly cap for those with private insurance.
- Eli Lilly and Novo Nordisk, the other two major insulin makers in the US, have also announced changes to how they price their insulin this month.
- The Inflation Reduction Act and the actions of the three major insulin makers are a step in the right direction, but more needs to be done to ensure that everyone has access to the medications they need.
In response to the Inflation Reduction Act, which set a $35 cap per insulin prescription per month for Medicare beneficiaries, Sanofi, one of the three major insulin makers in the United States, has announced a 78% reduction in the list price of its most widely prescribed insulin, Lantus, and a $35 monthly cap for those with private insurance. Uninsured Americans are eligible for Sanofi’s Insulins Valyou Savings Program.
President Joe Biden praised the move in a statement on Thursday, saying, “As of this afternoon, all three of the leading insulin producers in America have agreed to substantially reduce their prices, following my calls to expand my $35 cap for seniors to all Americans.”
In addition to the reduction in Lantus prices, Sanofi is also cutting the list price of its short-acting Apidra insulin by 70%. Eli Lilly and Novo Nordisk, the other two major insulin makers in the US, have also announced changes to how they price their insulin this month. Together, the three drugmakers make up roughly 90% of the insulin market in the U.S.
The move is part of a larger effort to make insulin more accessible and affordable for people with diabetes. The Inflation Reduction Act and the actions of the three major insulin makers are a step in the right direction, but more needs to be done to ensure that everyone has access to the medications they need.
Be First to Comment